U-63557A
U-63557A Basic information
- Product Name:
- U-63557A
- Synonyms:
-
- SODIUM FUREGRELATE
- U-63557A
- FUREGRELATE SODIUM
- FUREGRELATE SODIUM SALT
- 5-(3-PYRIDINYLMETHYL)-2-BENZOFURANCARBOXYLIC ACID, SODIUM SALT
- 5-[3,PYRIDINYLMETHYL]BENZO-FURAN-CARBOXYLIC ACID SODIUM SALT
- furegralate sodium
- 5-(3-Pyridinylmethyl)benzofurancarboxylic acid sodium-potassium salt
- CAS:
- 85666-17-7
- MF:
- C15H12NNaO3
- MW:
- 277.25
- Mol File:
- 85666-17-7.mol
U-63557A Chemical Properties
- storage temp.
- −20°C
- solubility
- DMF: >25 mg/ml; DMSO: >21 mg/ml; Ethanol: >14.5 mg/ml; PBS pH 7.2: >16.5 mg/ml
- form
- White to off-white crystalline solid.
- color
- White to light yellow
- Water Solubility
- Soluble in water at approximately 15mg/ml
U-63557A Usage And Synthesis
Uses
Inhibitor (thromboxane synthetase).
Uses
Furegrelate Sodium (U-63557A) is a selective and potent thromboxane A2 synthase (TXA2R) inhibitor in platelets.
in vivo
Furegrelate Sodium (1-5 mg/kg; po) prevents blockage of the coronary artery[1].
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1].
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2].
Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostagcyclin analogues; And Furegrelate is highly specific to the target enzyme[2].
| Animal Model: | Mongrel dogs (19-30 kg)[1] |
| Dosage: | 1-5 mg/kg |
| Administration: | Oral (via a gastric tube) |
| Result: | Prevented blockage of the coronary artery. |
U-63557ASupplier
- Tel
- 021-62219190; 18321139117
- 316441092@qq.com
- Tel
- 16314854226
- info@bocsci.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 15971444841
- amber@biochempartner.com